{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:17:32Z","timestamp":1787771852997,"version":"build-2784847793"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Psoriatic arthritis (PsA) is a chronic systemic inflammatory disease characterized by joint inflammation associated with cutaneous psoriasis. For many years, the amount of attention directed to PsA had been less than that for various other arthropathies. With the advances in understanding its pathogensis, it is now recognized as a distinct disease entity with characteristic features. Psoriatic arthritis has a greater tendency towards asymmetric oligoarticular involvement, distal interphalangeal involvement and spondylitis. Associated features such as enthesitis and dactylitis are more common. Specific radiological features include ankylosis and bone resorption. With the availability of potent new therapeutic agents for psoriasis and PsA, interest in research and clinical care for these conditions has been reinvigorated. Anti-TNF therapy has achieved encouraging efficacy in both the joints and skin disease, improving function and quality of life and inhibiting radiological progression measured in patients with PsA and psoriasis. Biologic agents may have the potential in addressing the unmet medical need in patients with PsA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0022-3859.30334","type":"journal-article","created":{"date-parts":[[2009,2,26]],"date-time":"2009-02-26T01:27:48Z","timestamp":1235611668000},"page":"63-71","source":"Crossref","is-referenced-by-count":28,"title":["Psoriatic arthritis as a distinct disease entity"],"prefix":"10.4103","volume":"53","author":[{"given":"YY","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LS","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EW","family":"Kun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EK","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-22-20240205","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: Epidemiology, clinical features, course and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R2-22-20240205","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum"},{"key":"R3-22-20240205","first-page":"127","article-title":"Psoriatic arthritis (PSA)- An analysis of 220 patients","volume":"62","author":"Gladman","year":"1987","journal-title":"Q J Med"},{"key":"R4-22-20240205","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/rheumatology\/30.5.339","article-title":"A re-evaluation of the osteoarticular manifestations of psoriasis","volume":"30","author":"Helliwell","year":"1991","journal-title":"Br J Rheumatol"},{"key":"R5-22-20240205","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/rheumatology\/38.4.332","article-title":"Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis","volume":"38","author":"Marsal","year":"1999","journal-title":"Rheumatology (Oxford"},{"key":"R6-22-20240205","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/rheumatology\/30.4.245","article-title":"Psoriatic arthritis (PA): A clinical, immunological and radiological study of 180 patients","volume":"30","author":"Torre Alonso","year":"1991","journal-title":"Br J Rheumatol"},{"key":"R7-22-20240205","first-page":"446","article-title":"Proposed classification criteria of psoriatic arthritis: A preliminary study in 260 patients","volume":"66","author":"Fournie","year":"1999","journal-title":"Rev Rhum"},{"key":"R8-22-20240205","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R9-22-20240205","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMra041320","article-title":"Psoriasis","volume":"352","author":"Schon","year":"2005","journal-title":"N Engl J Med"},{"key":"R10-22-20240205","first-page":"1752","article-title":"Reda DJ. Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: Analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies","volume":"26","author":"Cohen","year":"1999","journal-title":"J Rheumatol"},{"key":"R11-22-20240205","first-page":"586","article-title":"HLA antigens in psoriatic arthritis","volume":"13","author":"Gladman","year":"1986","journal-title":"J Rheumatol"},{"key":"R12-22-20240205","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2133.1982.tb00924.x","article-title":"Response to injury of skin involved and uninvolved with psoriasis and its relation to disease activity: Koebner and 'reverse' Koebner","volume":"106","author":"Eyre","year":"1982","journal-title":"Br J Dermatol"},{"key":"R13-22-20240205","first-page":"CD001976","article-title":"Antistreptococcal interventions for guttate and chronic plaque psoriasis","volume":"2","author":"Owen","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"R14-22-20240205","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00001432-200004000-00002","article-title":"Retroviruses and psoriasis","volume":"13","author":"Mallon","year":"2000","journal-title":"Curr Opin Infect Dis"},{"key":"R15-22-20240205","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/art.1780390912","article-title":"Dactylitis in patients with seronegative spondylarthropathy. Assessment by ultrasonography and magnetic resonance imaging","volume":"39","author":"Olivieri","year":"1996","journal-title":"Arthritis Rheum"},{"key":"R16-22-20240205","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R17-22-20240205","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial","volume":"64","author":"Antonic","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R18-22-20240205","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R19-22-20240205","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/art.10841","article-title":"Report on the Second international Enthesitis Workshop","volume":"48","author":"McGonagle","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R20-22-20240205","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/1529-0131(199906)42:6<1080::AID-ANR2>3.0.CO;2-7","article-title":"Psoriatic arthritis: A unified concept twenty years on","volume":"42","author":"McGonale","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R21-22-20240205","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1002\/art.20566","article-title":"The \"enthesis organ\" concept: Why enthesopathies may not present as focal insertional disorders","volume":"50","author":"Benjamin","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R22-22-20240205","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/ard.46.3.197","article-title":"Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis","volume":"46","author":"Mander","year":"1987","journal-title":"Ann Rheum Dis"},{"key":"R23-22-20240205","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.62.2.127","article-title":"Assessment of enthesitis in ankylosing spondylitis","volume":"62","author":"Heuft-Dorenbosch","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R24-22-20240205","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0950-3579(94)80022-7","article-title":"The SAPHO syndrome","volume":"8","author":"Kahn","year":"1994","journal-title":"Baillieres Clin Rheumatol"},{"key":"R25-22-20240205","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/rheumatology\/33.2.133","article-title":"Classification of clinical subsets in psoriatic arthritis","volume":"33","author":"Veale","year":"1994","journal-title":"Br J Rheumatol"},{"key":"R26-22-20240205","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4103\/0378-6323.16622","article-title":"SAPHO syndrome treated with pamidronate","volume":"71","author":"Tehrani","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R27-22-20240205","first-page":"1553","article-title":"Incidence of osteoperiostitis of the great toe in psoriatic arthritis","volume":"23","author":"Goupille","year":"1996","journal-title":"J Rheum"},{"key":"R28-22-20240205","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2004.030809","article-title":"Psoriatic arthritis imaging: A review of scoring methods","volume":"64","author":"van der Heijde","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R29-22-20240205","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N","article-title":"Mortality studies in psoriatic arthritis: Results from a single outpatient center. II. Prognostic indicators for death","volume":"41","author":"Gladman","year":"1998","journal-title":"Arthritis Rheum"},{"key":"R30-22-20240205","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/archderm.1994.01690020082014","article-title":"The genetics of psoriasis","volume":"130","author":"Elder","year":"1994","journal-title":"Arch Dermatol"},{"key":"R31-22-20240205","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/ard.32.3.181","article-title":"Familial occurrence of psoriatic arthritis","volume":"32","author":"Moll","year":"1973","journal-title":"Ann Rheum Dis"},{"key":"R32-22-20240205","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0190-9622(85)70188-0","article-title":"Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris","volume":"13","author":"Henseler","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"R33-22-20240205","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1093\/hmg\/6.8.1349","article-title":"Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan","volume":"6","author":"Nair","year":"1997","journal-title":"Hum Mol Genet"},{"key":"R34-22-20240205","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s004399900182","article-title":"A genome-wide search for genes predisposing to familial psoriasis by using a stratification approach","volume":"105","author":"Samuelsson","year":"1999","journal-title":"Hum Genet"},{"key":"R35-22-20240205","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1086\/378076","article-title":"CARD15: A pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis","volume":"73","author":"Rahman","year":"2003","journal-title":"Am J Hum Genet"},{"key":"R36-22-20240205","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00403-005-0624-2","article-title":"CARD15 mutations in patients with plaque-type psoriasis and psoriatic arthritis: Lack of association","volume":"297","author":"Jenisch","year":"2006","journal-title":"Arch Dermatol Res"},{"key":"R37-22-20240205","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/ard.61.3.213","article-title":"Differential association of polymorphisms in the TNFa region with psoriatic arthritis but not psoriasis","volume":"61","author":"Hohler","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R38-22-20240205","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.10935","article-title":"Cytokine gene polymorphisms: Association with psoriatic arthritis susceptibility and severity","volume":"48","author":"Balding","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R39-22-20240205","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/ard.2004.031740","article-title":"Immunopathology of psoriasis and psoriatic arthritis","volume":"65","author":"Veale","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R40-22-20240205","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: Safety, efficacy and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R41-22-20240205","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept","volume":"33","author":"Mease","year":"2006","journal-title":"J Rheumatol"},{"key":"R42-22-20240205","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1749-6632.1999.tb07743.x","article-title":"Synovial cytokine and growth factor regulation of MMPs\/TIMPs: Implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients","volume":"878","author":"Fearon","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"R43-22-20240205","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1172\/JCI200316069","article-title":"Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis","volume":"111","author":"Ritchlin","year":"2003","journal-title":"J Clin Invest"},{"key":"R44-22-20240205","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780390118","article-title":"Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis","volume":"39","author":"Pitzalis","year":"1996","journal-title":"Arthritis Rheum"},{"key":"R45-22-20240205","first-page":"809","article-title":"Longitudinal study of clinical and radiological progression in psoriatic arthritis","volume":"17","author":"Gladman","year":"1990","journal-title":"J Rheumatol"},{"key":"R46-22-20240205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","article-title":"Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis","volume":"45","author":"Husted","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R47-22-20240205","first-page":"86","article-title":"Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis","volume":"33","author":"Zink","year":"2006","journal-title":"J Rheumatol"},{"key":"R48-22-20240205","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0002-9343(91)90667-M","article-title":"Methotrexate and histologic hepatic abnormailities: A meta-analysis","volume":"90","author":"Whiting-O","year":"1991","journal-title":"Am J Med"},{"key":"R49-22-20240205","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis-Oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"R50-22-20240205","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/ard.2005.045658","article-title":"The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): Results of radiographic analyses after 1 year","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R51-22-20240205","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000069965","article-title":"Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy","volume":"206","author":"Devos","year":"2003","journal-title":"Dermatology"},{"key":"R52-22-20240205","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: A large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R53-22-20240205","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, A tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"R54-22-20240205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/ard.62.suppl_2.ii37","article-title":"Role of tumour necrosis factor (TNF) in host defence against tuberculosis: Implications for immunotherapies targeting TNF","volume":"62","author":"Ehlers","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R55-22-20240205","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R56-22-20240205","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R57-22-20240205","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R58-22-20240205","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/art.21870","article-title":"Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebo-controlled study","volume":"54","author":"Mease","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R60-22-20240205","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/sarh.2002.28798","article-title":"Clinical features and predictive factors in psoriatic arthritis-related uveitis","volume":"31","author":"Queiro","year":"2002","journal-title":"Semin Arthritis Rheum"}],"container-title":["Journal of Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005257-200753010-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:17:53Z","timestamp":1787768273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005257-200753010-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.4103\/0022-3859.30334","relation":{},"ISSN":["0022-3859"],"issn-type":[{"value":"0022-3859","type":"print"}],"subject":[],"published":{"date-parts":[[2007]]}}}